Vaccination of piglets at 1 week of age with an inactivated Mycoplasma hyopneumoniae vaccine reduces lung lesions and improves average daily gain in body weight

Wilson, Stephen E.; Brussel, Leen Van; Saunders, Gillian; Taylor, Lucas; Zimmermann, Lisa; Heinritzi, K.; Ritzmann, M.; Banholzer, E.; Eddicks, Matthias

doi:10.1016/j.vaccine.2012.10.028

Cited by 23 publications

(23 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It was surprising that no difference was found between lung lesions and ADG, since this correlation has been observed in several studies e.g. [8-10], although missing in another [11]. The lack of correlation between lung lesions and growth rate, together with the low ADG seen in the study, could be explained by the fact that a batch of pigs was weighed when the first pig within the batch reached slaughter weight.…”

Section: Discussionmentioning

confidence: 62%

A field evaluation of two vaccines against Mycoplasma hyopneumoniae infection in pigs

et al. 2014

View full text Add to dashboard Cite

BackgroundA field trial was carried out with two Mycoplasma hyopneumoniae vaccines in order to investigate the benefit of vaccination under field conditions in modern Danish pig production facilities with pigs being positive for M. hyopneumoniae. The M. hyopneumoniae infection of the herd was confirmed through blood samples that were positive for antibodies against M. hyopneumoniae combined with gross lesions of the lungs related to M. hyopneumoniae at slaughter and detection of M. hyopneumoniae by polymerace chain reaction in these lesions.ResultsA total of 2,256 pigs from two herds were randomly divided into three groups. Group 1 received 2 mL ThoroVAX®VET, Group 2 received 1 mL Ingelvac®MycoFLEX, and Group 3 was a non-vaccinated control group. The vaccination was performed by a person who was not involved in the rest of the trial and vaccination status thereby blinded to the evaluators.The prevalence of lung lesions related to M. hyopneumoniae were significantly lower for pigs vaccinated with ThoroVAX®VET but not for pigs vaccinated with Ingelvac®MycoFLEX®, when compared to non-vaccinated pigs. There was no significant effect of vaccination on growth rate, antibiotic consumption or mortality.ConclusionThis trial demonstrated that vaccination with Thoro®VAX VET was effective in reducing the prevalence of lung lesion in pig units infected with M. hyopneumoniae.

show abstract

Section: Discussionmentioning

confidence: 62%

A field evaluation of two vaccines against Mycoplasma hyopneumoniae infection in pigs

et al. 2014

View full text Add to dashboard Cite

show abstract

“…vaccinated pigs had significantly higher antibody titers and significantly smaller amounts of Mycoplasma hyopneumoniae DNA (as determined from DNA quantification) isolated from bronchial swab specimens and lung tissue samples collected at necropsy, 4 weeks after the challenge. As the existing product profile did not claim benefits for production parameters, this was not evaluated in the laboratory efficacy (onset of immunity) studies; however, other studies conducted by us did show performance advantages (body weight, average daily gain) in the field environment (10). We demonstrated previously that early (at less than 1 week of age) vaccination of pigs with Suvaxyn MH-One is efficacious in the field environment (10).…”

Section: Discussionmentioning

confidence: 99%

“…We demonstrated previously that vaccination of piglets with an inactivated M. hyopneumoniae vaccine (Suvaxyn MH-One; Zoetis) at less than 1 week of age (4 to 5 days old) under field conditions significantly reduces lung lesions and also reduces body weight losses (10). The efficacy of single-shot vaccines against M. hyopneumoniae at commercial-release titers, when administered to 1-week-old pigs in the presence of maternal antibodies, has been demonstrated previously (11,12).…”

mentioning

confidence: 99%

Vaccination of Piglets up to 1 Week of Age with a Single-Dose Mycoplasma hyopneumoniae Vaccine Induces Protective Immunity within 2 Weeks against Virulent Challenge in the Presence of Maternally Derived Antibodies

Wilson

Brussel

Saunders

et al. 2013

Clin. Vaccine Immunol.

Self Cite

View full text Add to dashboard Cite

bEnzootic pneumonia, resulting from infection with Mycoplasma hyopneumoniae, is of considerable economic importance to the pig industry and normally is controlled through active vaccination of piglets. We have demonstrated that administration of an inactivated Mycoplasma hyopneumoniae vaccine to piglets less than 1 week old is efficacious under field conditions and reduces the level of lung lesions observed in comparison to that in control pigs. Here, the results of two separate studies, one in piglets with and the second one in piglets without maternal antibodies, conducted to satisfy the requirements of the European Pharmacopoeia (monograph no. 07/2009:2448), are reported. Piglets received either minimal titer Suvaxyn MH-One or saline at less than 1 week of age and were challenged with Mycoplasma hyopneumoniae 2 weeks later. The number of lung lesions was recorded 4 weeks after challenge, and bronchial swab and lung tissue specimens were analyzed for quantification of Mycoplasma hyopneumoniae DNA. In the presence and absence of maternal antibodies, vaccination of piglets at less than 1 week of age was efficacious, with vaccinated piglets having significantly lower percentages of lung with lesions and lower Mycoplasma hyopneumoniae counts detected in bronchial swab and lung tissue specimens at necropsy. In conclusion, the vaccination of piglets at 1 week of age with Suvaxyn MH-One is efficacious in the presence of high levels of maternal antibodies. E nzootic pneumonia in pigs is a serious problem for commercial operations. The disease can result from infection with Mycoplasma hyopneumoniae, is characterized mainly by a nonproductive cough (1), and is responsible for considerable economic losses in pig production worldwide (2, 3), resulting from higher feed conversion, decreased body weight gains, and increased medication costs. Studies have shown that infection with M. hyopneumoniae also predisposes pigs to subsequent infection by other bacterial pathogens, such as Actinobacillus (formerly Haemophilus) pleuropneumoniae (4), or Pasteurella multocida (5). Apart from coinfections, factors such as the management of the animals, their environment, and their general health status can also affect the severity of mycoplasmal disease. Therefore, strategies for the control of enzootic pneumonia are extremely important in pig production.The majority of piglets in commercial systems are routinely vaccinated against M. hyopneumoniae, and numerous studies have evaluated the efficacy and safety of vaccines under field conditions (6-8). Vaccination of pigs has been shown to reduce body weight losses and the prevalence of pigs actually observed with (pneumonic) lung lesions, as well as the severity of lesions in those pigs that are affected. Piglets are often infected by M. hyopneumoniae from their mothers (3), and field prevalence studies have indicated that between 1.5% and 4% of 1-and 3-week-old piglets tested with either nasal swabs or necropsies show positive PCR results for M. hyopneumoniae (9).We demonstrated previously...

show abstract

“…Vaccination is a very common control measure which has been extensively proven to reduce performance losses, the severity of clinical signs and lung lesions (Maes and others 1998, 1999, Jensen and others 2002, Wilson and others 2012, Del Pozo Sacristán and others 2014). …”

Section: Introductionmentioning

confidence: 99%

Mycoplasma hyopneumoniaevaccination at or shortly before weaning under field conditions: a randomised efficacy trial

et al. 2017

View full text Add to dashboard Cite

This study assessed the efficacy of two different Mycoplasma hyopneumoniae vaccination programmes in relation to the time of weaning. Eight hundred and twenty-eight piglets were randomly divided into three groups: group V1 was vaccinated three days before weaning, group V2 at weaning (21 days of age) and group NV was left non-vaccinated. Vaccinations were performed using Ingelvac MycoFLEX. After the nursery period, 306 pigs were allocated to fattening unit (F1) and 501 pigs to a second unit (F2). Efficacy was evaluated using performance parameters and pneumonia lesions at slaughter. Statistically significant differences were obtained in F2 where group V1 had a higher average daily weight gain compared to groups V2 and NV for the entire study period (17 and 18 g/day, respectively) and the fattening period (26 and 36 g/day, respectively) (P<0.05). Considering respiratory disease scores for both fattening units, group V1 was the only group where coughing severity did not increase significantly between placement and the end of the fattening period (P>0.05). Between groups, there were no statistically significant differences for the average lung lesion scores (V1=3.44; V2=4.61; NV=4.55, P>0.05) and the prevalence of pneumonia (V1=35.0 per cent; V2=38.0 per cent; NV=41.4 per cent, P>0.05). Overall, vaccination against M hyopneumoniae before weaning provided numerically better performance than vaccination at weaning, but did not reach statistical significance. An influenza outbreak in F1 and the presence of coexisting mixed respiratory infections in both F1 and F2 could have possibly influenced the performance of both vaccinated groups across all measured parameters.

show abstract

Vaccination of piglets at 1 week of age with an inactivated Mycoplasma hyopneumoniae vaccine reduces lung lesions and improves average daily gain in body weight

Cited by 23 publications

References 9 publications

A field evaluation of two vaccines against Mycoplasma hyopneumoniae infection in pigs

A field evaluation of two vaccines against Mycoplasma hyopneumoniae infection in pigs

Vaccination of Piglets up to 1 Week of Age with a Single-Dose Mycoplasma hyopneumoniae Vaccine Induces Protective Immunity within 2 Weeks against Virulent Challenge in the Presence of Maternally Derived Antibodies

Mycoplasma hyopneumoniaevaccination at or shortly before weaning under field conditions: a randomised efficacy trial

Contact Info

Product

Resources

About